## **Press Cutting**

Client: Chi-Med

Publication: Investor's Business Daily

Date: 21 December 2011

## AstraZeneca signs two deals

The pharmaceutical will pay Hutchison China MediTech \$20 mil to help develop a cancer-fighting drug. It bought options on a potential diabetes pills from Astellas Pharma .

But both products are still in early development phases and won't alleviate worries of a lack of new drugs from AstraZeneca (AZN). The firm reported a loss of \$380 mil on failed studies for depression and cancer-treating drugs.

Its Crestor cholesterol-reducing drug faces competition from generics of Pfizer's (PFE) Lipitor drug. AstraZeneca dipped 0.2% to 45.43.

